Tacrolimus treatment saved a rho-incompatible pregnancy

Area of Science:

• Immunology
• Maternal-Fetal Medicine
• Reproductive Medicine

Background:

• Rh-incompatible pregnancies pose risks including fetal anemia, hydrops, and intrauterine fetal death.
• Recurrent implantation failure is a significant challenge in assisted reproductive technologies.
• Alloimmunization can complicate subsequent pregnancies, leading to antibody production against fetal antigens.

Purpose of the Study:

• To evaluate the efficacy of tacrolimus in managing a Rh-incompatible pregnancy with a history of recurrent implantation failures.
• To assess tacrolimus's role in suppressing anti-D antibody production during pregnancy.
• To determine if tacrolimus can maintain pregnancy stability in alloimmunized patients.

Main Methods:

• Treatment of a Rh-incompatible pregnancy with tacrolimus.
• Monitoring of T helper type 1 (Th1) cell populations throughout gestation.
• Dosage adjustment of tacrolimus based on Th1 cell levels at 28-week gestation.

Main Results:

• Tacrolimus treatment led to a successful second pregnancy after recurrent implantation failures.
• The patient's Th1 cell population remained elevated, necessitating increased tacrolimus dosage.
• Tacrolimus effectively suppressed anti-D antibody production, ensuring pregnancy stability.

Conclusions:

• Tacrolimus is a viable therapeutic option for managing Rh-incompatible pregnancies in alloimmunized women.
• Continued tacrolimus treatment, with dose adjustments, can prevent fetal complications and antibody formation.
• This case highlights tacrolimus's potential in overcoming infertility and immunological challenges in alloimmunized pregnancies.